Traxion Therapeutics

Cognetix is a biopharmaceutical company that is developing peptide therapeutics for the treatment of epilepsy, pain and anesthesia. The company's research and development efforts are focused on conopeptides which are peptides derived from the venom of predatory sea snails. Per the company, Cognetix has corporate collaborations in place with Medtronic, Inc. and Elan Corporation plc.

TheraVasc is a privately-held biotechnology company with offices in Louisiana, focused on the development of vascular therapies with decreased risks through the repositioning of drugs with known safety profiles. The Company's first program is for the treatment of peripheral artery disease (PAD). PAD is a chronic disorder associated with reduced blood flow to the extremities, affecting some 14 million Americans and hundreds of millions of people across the world. This disease causes severe pain in the extremities, limiting mobility and in some cases, leads to death. Unfortunately, there are no treatments available for this disease. TheraVasc's lead product, TV1001i, selectively increases blood flow in ischemic tissues affected in PAD.

Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's core technology is based on research which showed that in many neuropathic pain conditions, the signal that triggers pain actually arises at the level of the skin. This finding provides a strong biological rationale for developing topically delivered drugs to target the pain at the source - the pain receptors in the skin. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain. ARC-4558 is a topical 0.1% clonidine gel being developed for the treatment of painful diabetic neuropathy (PDN). It is a clear, water-based, fast-drying gel that provides pain relief that rivals approved oral drugs. ARC-4558 has a minimal side-effect profile with low/undetectable systemic levels of clonidine with over 600 patients treated in clinical trials to date.

ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a high proportion of common surgical procedures causing pain and dysfunction in millions of patients worldwide.

CELLective Dx is an early-stage company developing a new generation of diagnostic tools for cancer based on analysis of CTCs directly from a patient's blood. Our novel proprietary technologies combine microfluidics, flow dynamics, cell biology, molecular biology, biochemistry, and surface chemistry to capture and analyze rare CTCs in blood more rapidly and effectively than other current technologies. CELLective Dx is developing simple, rapid, blood-based cancer tests that will provide physicians and patients with accurate and individualized clinical information on disease status, treatment selection, and treatment response that will dramatically improve the clinical management of cancer.

Hunter-Fleming is a biopharmaceutical company developing new medicines to treat neurological and cardiovascular disorders. The company focus is on unmet patient needs in dementias such as Alzheimer's disease, as well as other important conditions such as neuropathic pain, head and spinal cord injuries and myocardial infarction.